The study design consists of a 4- to 16-week dose escalation stage, a 12- to 28-week efficacy evaluation and maintenance stage at doses that maintain hematocrit levels in the desired range of less than 45 percent, and randomized and blinded withdrawal stage for up to 12-weeks.
The study has an open-label extension for up to one year. Dosing is provided by self-administered subcutaneous injection, usually at weekly intervals.
The study protocol allows for accommodations during the COVID-19 pandemic, e.g., allowing for local delivery of study medication and alternative study visits (phone or virtual visits), as needed.
The objectives of the study are to assess: